InsidersTradesSigma
Follow the 아스테라시스 stock price and the full directors' dealings record of the company, a listed issuer based in South Korea. Shares are quoted on the KR market, under the authority of DART (FSS). Operating in the Health Care sector, 아스테라시스 has published 34 insider filings. Market capitalisation: €215.2bn. The latest transaction was filed on 16 July 2026 (Sale). Among the most active insiders: 서은택. All data is openly available.
32
Insider Decl.
n/a
Thresholds
n/a
17 ops.
Buy Volume
n/a
2 ops.
Sell Volume
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 5,068 of 29,063 companies
68.4
score / 100
Value48
Quality88
FCF yld1.7%
Earn yld4.6%
EV/EBITDA15.9x
ROE19%
Gross mgn79%
Net mgn24%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 16 July 2026
Declarations34 total
Other
Other
25 of 34 declarations
About 아스테라시스
Asterasis is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX. It focuses on developing innovative solutions to enhance healthcare.